Merck Ventures-backed ReproNovo named to Fierce Biotech’s 2026 “Fierce 15” list

By Public Technologies
  • Merck Ventures BV portfolio company ReproNovo was named to Fierce Biotech’s 2026 “Fierce 15” list of private biotech companies.
  • The recognition highlights ReproNovo’s work in fertility and women’s health, raising its profile with investors and potential partners.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck Ventures BV published the original content used to generate this news brief on October 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk